Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $1.98 Analyst target: $4.60 Upside: 132.32%
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
See the full interactive analysis & chart →Informational only — not investment advice.